Gilead Sciences, Inc. $GILD Shares Sold by Forsta AP Fonden

Forsta AP Fonden trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 262,000 shares of the biopharmaceutical company’s stock after selling 6,500 shares during the period. Forsta AP Fonden’s holdings in Gilead Sciences were worth $32,158,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Norges Bank purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $2,617,152,000. Cornerstone Select Advisors LLC raised its stake in Gilead Sciences by 9.3% during the fourth quarter. Cornerstone Select Advisors LLC now owns 14,334 shares of the biopharmaceutical company’s stock worth $1,759,000 after purchasing an additional 1,215 shares during the period. Eurizon Capital SGR S.p.A. purchased a new position in Gilead Sciences during the fourth quarter worth about $117,430,000. Triglav Investments D.O.O. raised its stake in shares of Gilead Sciences by 27.4% in the 4th quarter. Triglav Investments D.O.O. now owns 20,387 shares of the biopharmaceutical company’s stock valued at $2,502,000 after acquiring an additional 4,387 shares during the period. Finally, Zhang Financial LLC purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $204,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GILD. Citigroup lifted their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a report on Monday, April 13th. Morgan Stanley cut their price target on shares of Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Leerink Partners cut their price target on shares of Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Finally, Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Twenty-five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,000 shares of company stock worth $7,075,670 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $134.43 on Friday. The company has a 50-day simple moving average of $135.30 and a 200-day simple moving average of $134.09. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $166.90 billion, a PE ratio of 18.31 and a beta of 0.31. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.